The Aston Martin share price has risen 75% over the last year.

The company has several exciting ventures in the pipeline keeping shareholders interested. The most significant is an agreement with Mercedes Benz. This is providing AML with a powerful path to electrification.

Plus, through its Project Horizon operational efficiency plan, Aston Martin is improving the way it runs its facilities. Under new management, Aston Martin is aiming for long-term profitability and much-improved business performance.

Much improved financial position

Having emerged from bankruptcy no less than seven times in its 108-year lifetime, Aston Martin has experienced a turbulent financial existence.

And it was touch and go after the pandemic hit in 2020 whether it would face yet another insolvency. That’s because it faced a large overstock of sports cars in its dealer network.

Thankfully, due to several refinancing deals, and careful rebalancing of its supply and demand, the company is now in a more stable financial position.

Last year Aston Martin raised £800m in new equity and refinanced all its notes that were due to expire in 2023. Their expiry dates have now been extended to 2025/26.

This restructuring and streamlining of the business has greatly improved the stock’s financial stability, further enhancing investor confidence.

In its recently reported Q1 results, Aston Martin revenues soared, and losses were less than feared. Wholesale volumes were up 134% year-on-year, and Aston Martin has over £500m in cash on its balance sheet.

Furthermore, it supported its full-year guidance, gross margins improved, and Aston Martin even believes it could be cash flow positive by 2023.

Shareholder risks

Unfortunately, it’s not all good news. Earlier this week, Aston Martin announced it is suing Swiss car dealer Nebula Project and its board members. It accuses them of failing to pay some customer deposits for orders of Aston Martin’s Valkyrie sports car. The company estimates this will dent its full-year profits by up to £15m.

Meanwhile, the Delta variant of Covid-19 is rampaging around the UK, and there are concerns the vaccine won’t contain it. This could be detrimental to many stocks, particularly those in the luxury goods market.

Nevertheless, Aston Martin vehicles are status symbols and a luxury brand with rising demand.

According to Aston Martin’s director of investor relations, Charlotte Cowley, 90% of Aston Martins built are still in existence. I think this is a very impressive figure that shows the lasting quality of the cars.

Ultimately, I think there’s a lot to like about Aston Martin. It’s very much a speculative investment, but I may add a small allocation of the shares to my Stocks and Shares ISA.

The post Should I buy shares in Aston Martin Lagonda? appeared first on The Motley Fool UK.

More reading

• Aston Martin shares are now only 41p!
• There are hundreds of shares I’d rather buy than Aston Martin. Here’s why!
• These FTSE 250 stocks are tipped to rise 46% (or more) in the next year!
• Down 95%, what might it take for the Aston Martin share price to rise 2,000%?
• My personal warning for anyone tempted by the plunging Aston Martin share price

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

What does Sareum do?

Sareum is a small molecule drug company developing targeted therapeutics. However, it doesn’t do the initial research. Instead, the team learns from others in the game using a low-cost research outsource model.

The team looks for drug candidates they believe will go all the way through clinical trials. Sareum then further designs the chosen molecules in-house and commissions lab work to proceed.

For instance, some existing autoimmune treatments treat the disease but have terrible side effects like thrombosis or severe infection. The Sareum Holdings team believes the TYK2/JAK1 inhibitors within these treatments can be enhanced to generate quality drugs that work with the immune system, devoid of the terrible side effects.

It’s already taking these through preclinical trials to test for the optimum dose and evaluate toxicology levels.

The company does not plan to commercialise drugs. Instead, it progresses to early clinical trials (phase 1 or 2) but will then licence to a partner.

For instance, Sareum licensed its CHK1 inhibitor SRA737 cancer treatment to Sierra Oncology. And its association with Sierra has lent considerable credibility to Sareum stock.

Furthermore, it has also been running a Covid-19 research programme. This is to see if its candidate molecule SDC-1801 can treat a cytokine storm in Covid-19 patients, along with protection against bacterial pneumonia. Meanwhile, SDC-1801 is being researched to treat psoriasis and rheumatoid arthritis.

Penny stocks can be a money pit

Today, Sareum is a penny stock with a £209m market cap. Its share price is up 1,160% from its 52-week low and down 34% from its 52-week high.

Sareum may well have further to climb. But penny stocks are notoriously risky investments.

In mid-June, the company raised £1.4m from the distribution of 30m additional shares. One high-net-worth individual bought the shares after already buying £900k worth of shares on 1 June.

This money is to be used to progress its TYK2/JAK1 programmes into clinical development. But it will also be used as working capital. The buyer also received a five-year warrant, which can be sold when the share price is above 7p for five consecutive days. That’s only 11% higher than it is today.

Furthermore, the company will need to raise additional funds in the coming weeks to undertake clinical trials for its autoimmune indications and a potential Covid-19 application.

Will this top biotech slide or soar?

Based in the UK, Sareum became the third-best-performing European biotech small-cap company last year. I think much of the success of the Sareum share price is due to the Covid-19-related hyping of biotech stocks.

Unfortunately, penny stocks are volatile, and I think this share price could just as easily slide as soar. I think Sareum does have some enticing reasons to be bullish, but it’s too risky for me. When investing in pharma stocks I prefer an established company like AstraZeneca.

The post Should I invest in penny stock Sareum (LSE:SAR)? appeared first on The Motley Fool UK.

More reading

• Starting with nothing? Here’s why now is the perfect time to start building a passive income
• Decided not to bother with a Stocks and Shares ISA? You might be missing these 3 things!
• Why is everyone buying GSK shares?
• £10,000 invested in easyJet shares at the start of 2026 is now worth…
• 5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Altogether, the Main Market of the London Stock Exchange hosts over 1,000 companies from 100 countries. So, where to start is a valid question.

One popular stock in the past year has been ITM Power (LSE:ITM). It’s operating in the green hydrogen space. This is a trending sector with lots of momentum, but is also highly speculative.

The Motley Fool’s long-term-investing mindset means looking for quality companies to stand the test of time. That means companies with a competitive advantage, integrity, and that are preferably well established. A dividend is a nice addition that can help build wealth through the power of compounding.

The ITM share price is volatile

ITM Power manufactures integrated hydrogen energy systems. With global pressure on reducing our carbon footprint mounting, research into alternative green technologies like hydrogen is well under way.

Founded in 2001, ITM Power has been listed on the London Stock Exchange since 2004. During that time, the ITM share price has risen over 700%. However, its share price appeared to coast sideways during the decade between 2009 and 2019.

Then, between September 2019 and January this year, ITM shares rocketed over 1,500%. But they’ve been on a downward slide since then, and are over 40% below their January high.

Analyst price targets range between 310p and 867p. So, it’s currently at the lower end of the scale. Nevertheless, I think the January high was fuelled by an extraordinary level of retail investor mania at the time and is not a good benchmark for true value.

ITM Power’s financial outlook

In its last half-year report to the end of October 2020, the company showed an order backlog worth £124m plus £434m in the pipeline.

A June 10 trading update said this order backlog had increased to £154m with £607m in the pipeline. But total revenue is projected to drop from £5.4m last year to £4m this year. The reduction is due to Covid-19.

ITM Power expects to produce 50MW of electrolysers by 30 April 2022. 33MW are in the backlog, and the rest in the advanced stages of negotiation.

Notable hedge funds BlackRock and Canaccord took a stake in ITM in February. Fidelity Investments Canada and Robeco followed them. I think institutional investor interest shows a level of confidence in the firm.

Is this a good stock for a new investor?

Unfortunately, the company is loss-making, and losses for the full year to April 2020 were more than double those of the previous year. It’s taking its time to scale commercially, which is probably making investors impatient. Plus, there’s no dividend.

ITM Power has geared up its manufacturing and operational capacity, so it should be ready to hit the ground running as it moves into larger-scale projects. While there’s undoubtedly potential here, and it may well thrive, I’m not convinced it’s a good stock for a new investor.

That’s because I’d be wary of jumping into momentum-led sectors without confirming the credibility and longevity of the business. I think starting with FTSE 350 stocks is a safer and less volatile way for new investors to discover the world of stock market investing with plenty of growth potential on offer.

The post Is ITM Power (LSE:ITM) a good first stock for new investors? appeared first on The Motley Fool UK.

More reading

• Starting with nothing? Here’s why now is the perfect time to start building a passive income
• Decided not to bother with a Stocks and Shares ISA? You might be missing these 3 things!
• Why is everyone buying GSK shares?
• £10,000 invested in easyJet shares at the start of 2026 is now worth…
• 5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Butt is a philanthropist and paid himself at least £27m in 2019. Recent news shows he and his colleagues received a £110.8m payout for the latest financial year. Such a large payout as the pandemic continues puts Silchester under the spotlight after years of staying in the shadows.

Morrisons is not Silchester’s only deep value play

Yet, Silchester is not new to the scene and is a significant investor in several UK stocks with potential growth stories. These include GlaxoSmithKline (LSE:GSK), Mitie, Pearson, and Tesco (LSE:TSCO).  

So, as speculation continues, does Silchester have a keen eye for value?

I wrote about Tesco earlier in the week as I think its institutional investors will be meeting management in the coming weeks to encourage action that will benefit shareholders. Tesco is operating under new management, and investors are hopeful a dividend is in the offing.

But investors appear to be running out of patience. I imagine a management strategy, share buyback, or dividend, would go a long way to appeasing relations and improving the Tesco share price.

Tesco’s Q1 results were not outstanding, but they show resilience and signs of growth. E-commerce sales are high, generating 1.3m orders a week. Two-year sales growth came in over 81.6%, while one-year sales growth rose 22.2%. General merchandise sales rose 10.3%, and clothing sales are up 52.1%.

Considering Tesco shares are trading at the low end of analyst expectations, I think they look like a potential deep value investment.

Rise of the activists

With climate change, health initiatives, and political agendas ever-present, activist investor presence has a rising influence on the direction companies take.

Tesco is no stranger to investor activism. It already agreed to raise its sales of healthy foods to 65% by 2025, which Silchester didn’t oppose.

I don’t think investor activism is a bad thing. It can help steer the company in a customer-friendly direction while encouraging consumer loyalty and improving its ESG score.

I’m tempted to buy Tesco shares before its Q2 earnings call in October.

Interestingly, another of Silchester’s considerable holdings is GlaxoSmithKline, which just confirmed details of its consumer healthcare spin-off after months of speculation. This arm is expected to take some of the debt burdens from the leading company to focus on R&D.

GlaxoSmithKline has a Covid-19 vaccine in the works. But many believe it’s too little too late for the world’s top vaccine maker.

For this reason and a lack of profit-making in recent years, activist investor Elliot Advisors has been vocal lately. The firm suggests the group splits further.

I’ve found GlaxoSmithKline to be a disappointing investment. The GSK share price is down 2% in the past five years, despite a promising rise in 2019. For now, I’ll hold off on buying more shares. Time will tell if it’s a deep value investment.

The post Are Tesco (LON:TSCO) and GlaxoSmithKline (LON:GSK) deep value investments? appeared first on The Motley Fool UK.

More reading

• Think the soaring Tesco share price is too good to be true? Read this…
• Prediction: by December, £5,000 invested in UK shares will be worth…
• Amid geopolitical and AI risks, here’s how I’m positioning my ISA and SIPP in 2026
• My game plan for the next stock market crash
• Up just 1%: what’s going on with Tesco shares now?

Kirsteen owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline, Morrisons, Pearson, and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

A penny stock with promise

Nevertheless, since October 2020, the share price has climbed 144%. And brokers have been upgrading their valuations.

Earlier this month, Mitie released good FY21 results, showing trading resilience and a strengthened balance sheet. Its adjusted pre-tax profit fell to £46m from £69.9m but came in better than analyst predictions.

The company acquired Interserve, a facilities management business, in November. Since then, the acquisition has been performing ahead of expectations. Interserve is a low-margin business, but it’s helped Mitie enhance its footprint.

Mitie outsources a variety of workers including cleaners, security guards, and maintenance teams. With the pandemic creating an unprecedented need for intense cleaning regimes, its staff have been in high demand. And as the reopening accelerates, I think this is likely to continue.

The company is improving its security offerings too with technological advancements and is also an industry-leading AC and renewable energy contractor. These are another two areas of growing interest.

So, the potential for further growth is strong. And the company believes its 2022 profit will be “materially ahead” of its prior expectations.

Notable shareholder

Furthermore, another compelling argument for enhanced interest in this stock is that deep value fund Silchester is its biggest shareholder. Silchester has a close to 15% stake in Mitie, and it recently upped its investment in Morrisons to 15%. Shortly afterward, Morrisons received a potential takeover bid. As such, I think UK investors will be paying closer attention to Silchester’s portfolio in the coming months.

Financial outlook

Mitie has a forward price-to-earnings ratio of 12.7. And a £201m rights issue last summer helped it drastically reduce its net debt, while also funding the Interserve acquisition. But it cancelled its dividend after the pandemic struck and is holding off on resuming it until 2022 at the earliest.

Also worth noting, Project County sold its last 7% stake in Mitie last week. It acquired these shares through the Interserve acquisition and sold them when the lock-up period ended. This means the stock no longer has the potential for dilution (aka overhang) from the Interserve purchase.

All of the above sounds great, but it’s still quite speculative. Mitie is a penny stock emerging from a seven-year struggle. It might continue to rise, but I imagine it wouldn’t take much economic disruption for its share price to tumble. Being a low-margin business makes me nervous too, plus a lack of a dividend to sweeten it makes me reluctant to buy shares in Mitie today.

Besides, there are other FTSE 250 stocks I’d prefer to invest in for long-term rewards. Nevertheless, I do see potential and I’ll keep it on my watch list for now.

The post Is FTSE 250 penny stock Mitie (LSE:MTO) a good long-term investment? appeared first on The Motley Fool UK.

More reading

• Starting with nothing? Here’s why now is the perfect time to start building a passive income
• Decided not to bother with a Stocks and Shares ISA? You might be missing these 3 things!
• Why is everyone buying GSK shares?
• £10,000 invested in easyJet shares at the start of 2026 is now worth…
• 5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Multinational packaging business DS Smith (LSE:SMDS) thrived in the pandemic as e-commerce sales soared. That’s because the company makes much of the cardboard packaging online orders are delivered in. The DS Smith share price is up 26% in the past year, but it’s been fluctuating this past week. Will the pressure to meet ESG targets reduce the appeal of this FTSE 100 stock as a long-term investment?

Environmental concerns

Pressure is mounting on FTSE 100 businesses to cut carbon emissions. So DS Smith is investing in energy-efficient technologies and switching to cleaner fuels. It’s already achieved ISO 50001 certification, which will help it reduce its CO2  emissions by 30% per tonne by 2030.

Its paper mill in Croatia recently switched to green energy, which is projected to reduce its CO2 emissions there by 23% annually.

There’s also the likelihood of rising consumer pressure for more eco-friendly packaging options, which could be expensive. But it’s aware of this and has launched a mission to solve eco problems, including replacing plastics in its packaging. And it’s a global partner with the Ellen MacArthur Foundation, boosting its reuse and recycling focus.

A FTSE 100 takeover target

In March, rival packaging company Mondi was rumoured to be considering a takeover of DS Smith, but nothing came of it. However, it remains an attractive potential target.

When billionaire Warren Buffett refers to a company’s economic moat, he means its competitive advantage. I think DS Smith has this as the scale of its manufacturing and distribution network is impressive. Thanks to years of investment, it solves many of the challenges present in the e-commerce supply chain. This may well present a valuable addition to a growing business.

Even without any takeover bids on the table, I think the company offers value. Yet there are some concerns.

At the moment, manufacturing its paper means buying the raw materials cheaply when the market is down. But paper production becomes expensive when the price of raw materials rises.

This past year has seen a commodity boom, and rising costs are hurting its profit margins.

In its just-released full-year results, it said pre-tax profit to April 30, fell 38% to £231m year-on-year, and revenue dropped 1% to £5.98bn. Meanwhile, adjusted operating profit fell 24% to £502m. Covid-19 and inflation risks continue to present challenges. Higher costs of packaging, energy, transport and labour all contributed to recent losses.

Would I buy DS Smith shares?

Analyst targets for the DS Smith share price fall between 330p and 509p. At 421p, it’s currently at the halfway mark. Its market cap is £5.7bn, its price-to-earnings ratio is 29, with a forward P/E of 15, and earnings per share are 24p.

It’s also a FTSE 100 constituent, so it’s well-established and has a credible reputation. Today, the company confirmed a final dividend. Added to its interim dividend, this makes for a 2.8% yield on today’s share price. The dividend is also covered by 2 to 2.5 times earnings. Of course, if pandemic conditions worsen, then the dividend may be at risk of another cut.

Nevertheless, DS Smith is a packaging company, and packaging is in high demand. E-commerce is on the rise, and I don’t see that slowing any time soon. DS Smith counts companies such as Unilever, Danone, Diageo, and PepsiCo as clients, which are all quality international brands. I’d consider adding this FTSE 100 stock to my Stocks and Shares ISA.

The post Here’s a FTSE 100 stock forging an ESG-focused future appeared first on The Motley Fool UK.

More reading

• Starting with nothing? Here’s why now is the perfect time to start building a passive income
• Decided not to bother with a Stocks and Shares ISA? You might be missing these 3 things!
• Why is everyone buying GSK shares?
• £10,000 invested in easyJet shares at the start of 2026 is now worth…
• 5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

Kirsteen owns shares of Unilever. The Motley Fool UK has recommended DS Smith, Diageo, and Unilever. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

The Diageo share price climbed between March and June last year but had lost most of its gains by October. Since then, it has rebounded 39%.

Potential takeover target?

Back in 2015, an article about a possible bid sent Diageo’s share price soaring. The potential bidder was 3G Capital Partners, in which billionaire investor Warren Buffett has a stake. Nothing was ever confirmed, and Diageo called it “market speculation and rumour”.

3G Capital Partners had missed out on acquiring Unilever for $143bn in 2017. So, could it potentially look in Diageo’s direction again?

The amalgamation of big brands is becoming a popular way to build a powerhouse. And private equity is getting in on the action. 3G Capital already acquired Kraft Heinz and Restaurant Brands International. Plus, it has significant stakes in Singaporean internet company Sea, and online used car retailer Carvana, among others.

I think Diageo is is n attractive target as it’s a force to be reckoned with. It’s grown considerably since 2015. But at £80bn, its market cap is lower than Unilever’s. I wouldn’t rule it out as a takeover target.

Loyalty pays off

But I’m a long-term investor and I think DGE scores here too. Loyal shareholders who’ve stuck with Diageo over the past seven years enjoyed a rising dividend and benefited from share buybacks. The pandemic put a temporary halt to the dividend. And today Diageo shares are still slightly below their 2019 high. But I think it has scope for climbing further as the hospitality sector reopens.

In its May update, the company said it expects organic operating profit growth to reach at least 14% this year, beating analyst expectations. This led it to resume its return-of-capital scheme, which should deliver £1bn in shareholder payments by the end of next year, including £500m in share buybacks before November 2021.

Sustainability focus

Some 80% of Diageo’s carbon footprint comes from heat, mainly through its brewing and distilling operations. To offset this, it’s been making sustainability moves. These include planting trees to restore landscapes and a paper bottle launch later this year.

It’s also integrating sustainability, inclusion and positive drinking messages into each of its brands. I think this goes a long way to building consumer loyalty and longevity in brand awareness. For instance, linking Guinness with women’s rugby, and Smirnoff with PRIDE.

Risks to shareholders

While I like the look of Diageo’s future, shareholder risks remain. Inflation or a trade war would impact sales, the travel sector is an important money-spinner for the company and has not yet resumed full capacity. Plus, a focus on health could deter consumers from drinking alcohol. I think this unlikely, but it’s still a risk. 

But as a global operation servicing multiple sectors, it has a significant advantage. Diageo is at the forefront of the growth of ready-made drinks which is also driving the sector today. Its outlook is positive, the share buyback is a plus and its track record is excellent. I’d add Diageo shares to my Stocks and Shares ISA.

The post Should I buy shares in FTSE 100 alcohol stock Diageo (LSE:DGE)? appeared first on The Motley Fool UK.

More reading

• I asked ChatGPT if I should buy Aviva, Diageo or BAE Systems stock and it said…
• Prediction: Diageo shares could soar in the next 5 years if this happens…
• These FTSE 100 stocks are tipped to rise 53% (or more) in the next year!
• Stock-market crash: 5 lessons from major market meltdowns
• Why is everyone still selling Diageo shares?

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended Diageo. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Is a bidding war about to start?

Morrisons has long been subject to takeover rumours. Since it linked with Amazon, there have been speculation that Amazon could buy it. Moreover, the grocery sector is a popular space for cash generation and repeat business. So this is enticing private equity to the table. And it’s not the first major deal in the sector to emerge.

Two years ago, J Sainsbury and Walmart’s Asda attempted to merge into a £15bn behemoth, but the Competition and Markets Authority (CMA) blocked it. Walmart later sold Asda to a consortium for £6.8bn.

CD&R has a history of acquiring significant retailers. It gradually sold a 60% stake in B&M Retail, accruing around £1.5bn. Through its funds it owns Motor Fuel Group, it’s begun selling out of SmileDirectClub, and recently moved to buy UDG Healthcare for £2.6bn. So if it wants Morrisons badly enough, it could come back with a better offer.

Meanwhile, other private equity firms may start circling. For instance, 3G Capital recently failed in its takeover bid of Unilever and may be looking for another big deal.

Morrisons seems a lucrative target. Its origins date back to 1899, it’s a credible business, a major private-sector employer, and makes more than half the fresh food it sells. It has a loyal following and ramped up its home delivery initiative after the pandemic hit. Altogether, Morrisons knows the retail food space very well, and I think it will continue to thrive.

Could Sir Terry Leahy return?

The interesting twist in CD&R’s bid is that former Tesco CEO, Sir Terry Leahy, is a senior advisor to the firm. And Morrisons’ current executive leaders reported to Leahy when they worked at Tesco. So there are already relationships they may be looking to cultivate.

Sir Terry is the brains behind the Tesco Clubcard and its powerhouse of consumer data. He also shaped the wider strategy that made Tesco the grocery market leader.

Value hidden in plain sight

CD&R’s offer of 230p a share is a 27% increase on its current price. However, Morrisons rejected that on Saturday, saying it’s far too low.

Nevertheless, this could be enough to boost investor confidence, and Morrisons would therefore be subject to a short squeeze in the coming days. That’s because it’s seen rising short interest, and last week it was the fifth most heavily shorted UK stock.

It will be the little-known deep value fund Silchester that will probably have the most significant say in any potential deal for Morrisons. According to the London Stock Exchange, Silchester increased its shareholding in the FTSE 250 supermarket to 15% last week.

Morrisons’ price-to-earnings ratio (P/E) is 44, but its forward P/E is a more reasonable 12, and its dividend yield is 4%.

It doesn’t come without risk and has considerable debt. The high short interest indicates a bearish stance, and grocery is hugely competitive. Nevertheless, I like Morrisons both as a place to shop and as an investment, and this news reaffirms that. I’m considering buying Morrisons shares for its long-term prospects, not for a quick acquisition profit, but I’ll be watching this space with interest.

The post Potential takeover alert! Should I buy Morrisons shares? appeared first on The Motley Fool UK.

More reading

• Starting with nothing? Here’s why now is the perfect time to start building a passive income
• Decided not to bother with a Stocks and Shares ISA? You might be missing these 3 things!
• Why is everyone buying GSK shares?
• £10,000 invested in easyJet shares at the start of 2026 is now worth…
• 5 years ago, £5,000 bought 2,645 Barclays shares. But how many would it buy now?

John Mackey, CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Kirsteen owns shares of Amazon and Unilever. The Motley Fool UK owns shares of and has recommended Amazon. The Motley Fool UK has recommended B&M European Value, Morrisons, UDG Healthcare, and Unilever and has recommended the following options: long January 2022 $1,920 calls on Amazon and short January 2022 $1,940 calls on Amazon. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Investor pressure

Irish businessman Ken Murphy became the new Tesco CEO last October. He had big shoes to fill as previous CEO Dave Lewis had a strong track record and was popular with shareholders. The appointment of new CFO Imran Nawaz followed Murphy’s arrival in April.

Institutional investors respected Dave Lewis and previous CFO Alan Stewart. They were credited with turning Tesco around after the accounting scandal in 2014, which knocked shareholder confidence. Under their leadership, Tesco moved away from its foreign operations to concentrate on the UK.

Following the sale of its Asian operations earlier in the year, shareholders were rewarded with a special dividend worth almost £5bn. This kept them sweet at the beginning of the year.

Since the crew change, the company has been given the benefit of the doubt, allowing Murphy and Nawaz to find their feet and for the pandemic response to settle. Both men have impressive CVs, coming from Walgreens Boots Alliance and Tate & Lyle, respectively. So, investor expectations are high.

But patience is running thin, and I believe institutional investors are keen to see a share buyback to boost their investment value. The company didn’t announce a buyback in April, which I understand some investors were hoping for.

Tesco’s biggest shareholders include BlackRock, Schroders, Norges Bank, Vanguard, and Fidelity.

Institutional investors are a force to be reckoned with and Tesco will want to keep them onside. The institutions already backed activist investors last month to raise sales of healthy foods to 65% by 2025.

Therefore, I imagine they won’t want to wait until October to see what’s next. They’ll likely meet with management in the coming weeks to let them know what they expect. And I think they might apply pressure for serious strategy changes or a share buyback.

Tesco shows underlying strength

While the Q1 results were not outstanding, they compared year-on-year to a period of exceptionally high sales. It was the peak of the pandemic stockpiling, so I actually think growth in Q1 showed strength. UK & ROI sales were up 1.3% and sales at Booker rose 9.2%. But Tesco didn’t raise full year guidance, which may have disappointed some.

Analyst share price targets come in between 220p to 315p, so Tesco shares are currently trading at the lower end of the scale.

I believe the CEO and CFO must be motivated to impress investors. Their own track record has been exceptional, so they won’t want to taint that. Nawaz worked for Kraft Foods when it acquired Cadbury’s, and he has a history of bringing down costs.

Plus, the numbers show customers are still flocking to Tesco. And its wholesale division Booker is recovering strongly as the hospitality sector reopens.

So, I’m tempted to invest in Tesco shares and see what happens in October. If it does announce a buyback or a shake-up of some sort, I expect its share price will rebound. Tesco’s forward price-to-earnings ratio is a reasonable 12. And the 4% dividend yield is also attractive enough to make this a viable long-term investment.

The post Should I buy Tesco shares before October? appeared first on The Motley Fool UK.

More reading

• Think the soaring Tesco share price is too good to be true? Read this…
• Prediction: by December, £5,000 invested in UK shares will be worth…
• Amid geopolitical and AI risks, here’s how I’m positioning my ISA and SIPP in 2026
• My game plan for the next stock market crash
• Up just 1%: what’s going on with Tesco shares now?

Kirsteen owns shares of Tate & Lyle. The Motley Fool UK has recommended Schroders (Non-Voting) and Tesco. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

So much promise

While Aduhelm doesn’t cure Alzheimer’s, it claims to halt it, which promises a better quality of life for millions of sufferers. But its fast-tracked approval is a controversial decision, and many health professionals are unimpressed.

In fact, three FDA members have gone so far as to resign in response to the decision. That’s because it’s not completed all phases of trial that drugs usually have to go through. Accelerated approval appears to be triggered because those in need are desperately clinging to the hope it can bring.

Biogen will continue to pursue efficacy trials, but the results are likely to take years, and in the meantime, it’s free to sell and profit from the drug.

Unfortunately, like many new drugs, Aduhelm is expensive. But, at $56k a year, it’s eye-wateringly so. In fact, this is a new extreme for drug pricing and likely to receive extreme pushback from authorities in the future.

Nevertheless, approval is set to mean at least some sales. And these are predicted to reach between a potential $7.5bn and $50bn a year.

A boost to the Biogen share price

The Biogen share price has already soared in response. At almost $385, it’s up 33% in a week, but down 18% since its peak on 10 June. A year ago it was $260.

If the drug meets positive expectations, it could be a game-changer for Biogen and its stock price. But it remains under scrutiny, and if it doesn’t meet expectations, I think the share price is likely to take a hit.

With the Aduhelm news cushioning the share price, other bad news seems to be flying under the radar. In the past week, Biogen reported failed trial results in three pipeline drugs; another potential Alzheimer’s drug, an eye treatment, and a drug for depression. While the share price seems buoyant for now, these failures remind us of biotech shares’ risk.

It’s also a highly competitive industry, and other major players are lining up their versions of Alzheimer’s drugs for FDA approval.

When investing in biotech/pharma stocks, I prefer big established companies over growth stocks. For that reason, I’d potentially allocate a small number of Biogen shares to my portfolio. But I also like AstraZeneca (LSE: AZN) as a significant pharma player.

AstraZeneca has a lot to offer

AstraZeneca has seen its share price fluctuate in recent months. Today it’s trading around £83 a share, which is down 17% from its 52-week-high and up 24% from its 52-week-low.

Its collaboration with Oxford University to bring a Covid-19 vaccine to market has not gone as smoothly as hoped, which has affected the AZN share price along the way. Nevertheless, the FTSE 100 company has more to offer.

AstraZeneca has a highly revered division focused on developing cancer therapies. It also has a diabetes treatment, heart failure therapy, and respiratory drugs. Additionally, it’s in the process of acquiring Alexion, a company specialising in rare diseases.

Q1 results showed signs of growth and rising revenues. I think both companies have potential. But I’d choose AstraZeneca over Biogen as it feels like a steadier long-term investment.

The post Pharma stock investing: Biogen vs AstraZeneca appeared first on The Motley Fool UK.

More reading

• How to try and double the State Pension with just £30 a week
• £20,000 invested in AstraZeneca shares 5 years ago is now worth…
• What’s going on with the AstraZeneca share price now?
• 2 FTSE 100 blue-chips to consider for a new £20k Stocks and Shares ISA

Kirsteen has no position in any of the shares mentioned. The Motley Fool UK has recommended Biogen. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.